Sporadic inclusion body myositis: The genetic contributions to the pathogenesis

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Gang, Qiang ^a   Bettencourt, Conceição ^a   Machado, Pedro ^a   Hanna, Michael G ^a   Houlden, Henry ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Exome sequencing; Genes; Genetics; IBM; Inclusion body myopathy; Inclusion body myositis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; DYSFERLIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DQA1 ANTIGEN; HLA DR ANTIGEN; HLA DR3 ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; MITOCHONDRIAL DNA; MYOSIN HEAVY CHAIN; NOTCH4 RECEPTOR; PRESENILIN; PRION PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN;

AUTOIMMUNITY; CELL VACUOLE; DNA POLYMORPHISM; EMERY DREIFUSS MUSCULAR DYSTROPHY; EXOME; FAMILIAL DISEASE; FRONTOTEMPORAL DEMENTIA; GENE DELETION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENETICS; HEREDITY; HUMAN; INCLUSION BODY MYOSITIS; JOINT CONTRACTURE; LEUKOENCEPHALOPATHY; LIMB GIRDLE MUSCULAR DYSTROPHY; MAJOR HISTOCOMPATIBILITY COMPLEX; MYOPATHY; NEUROMUSCULAR DISEASE; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPHTHALMOPLEGIA; PATHOGENESIS; PROTEIN PHOSPHORYLATION; REVIEW; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SPORADIC INCLUSION BODY MYOSITIS; AUTOIMMUNE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETIC SUSCEPTIBILITY; INFLAMMATION; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE WEAKNESS;

HUMANS; MYOSITIS, INCLUSION BODY;

EID: 84902702309     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-88     Document Type: Review

References (110)

1. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL, J Clin Neurosci 2008 15 1350 1353
2. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Lindberg C, Persson LI, Bjorkander J, Oldfors A, Acta Neurol Scand 1994 89 123 131 (Pubitemid 24095268)
3. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, van den Hoogen F, Hoogendijk J, Howeler C, de Jager A, Jennekens F, Koehler P, van der Leeuw H, de Visser M, Verschuuren JJ, Wintzen AR, Neurology 2000 55 1385 1387
4. Incidence of rare systemic rheumatic and connective tissue diseases in Finland. Kaipiainen-Seppanen O, Aho K, J Intern Med 1996 240 81 84 (Pubitemid 26298129)
5. Prevalence of sporadic inclusion body myositis in Western Australia. Phillips BA, Zilko PJ, Mastaglia FL, Muscle Nerve 2000 23 970 972 (Pubitemid 30354508)
6. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Felice KJ, North WA, Medicine (Baltimore) 2001 80 320 327 (Pubitemid 32879294)
7. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. Wilson FC, Ytterberg SR, St Sauver JL, Reed AM, St Sauver JL, Reed AM, J Rheumatol 2008 35 445 447 (Pubitemid 351374418)
8. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey. Oflazer PS, Deymeer F, Parman Y, Acta Myol 2011 30 34 36
9. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. Suzuki N, Aoki M, Mori-Yoshimura M, Hayashi YK, Nonaka I, Nishino I, J Neurol 2012 259 554 556
10. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Tan JA, Roberts-Thomson PJ, Blumbergs P, Hakendorf P, Cox SR, Limaye V, Int J Rheum Dis 2013 16 331 338
11. Update in inclusion body myositis. Machado P, Brady S, Hanna MG, Curr Opin Rheumatol 2013 25 763 771
12. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Cortese A, Machado P, Morrow J, Dewar L, Hiscock A, Miller A, Brady S, Hilton-Jones D, Parton M, Hanna MG, Neuromuscul Disord 2013 23 404 412
13. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA, Brain 2011 134 3167 3175
14. Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Muntzing K, Lindberg C, Moslemi AR, Oldfors A, Scand J Immunol 2003 58 195 200 (Pubitemid 36904312)
15. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. Askanas V, Engel WK, J Neuropathol Exp Neurol 2001 60 1 14 (Pubitemid 32097001)
16. Mitochondrial abnormalities in inclusion-body myositis. Oldfors A, Moslemi AR, Jonasson L, Ohlsson M, Kollberg G, Lindberg C, Neurology 2006 66 49 S55
17. Inclusion body myositis and myopathies. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP, Ann Neurol 1995 38 705 713
18. Inclusion body myositis. Tawil R, Griggs RC, Curr Opin Rheumatol 2002 14 653 657 (Pubitemid 35191551)
19. Inclusion body myositis. Verschuuren JJ, Badrising UA, Van Engelen BG, Van der Hoeven JH, Hoogendijk J, Wintzen AR, Diagnostic Criteria for Neuromuscular Disorders London: Royal Society of Medicine Press, Emery AEH, 1997 81 84
20. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Rose MR, Neuromuscul Disord 2013 23 1044 1055
21. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG, Neuromuscul Disord 2010 20 142 147
22. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Benveniste O, Hilton-Jones D, Neuromuscul Disord 2010 20 414 421
23. Pathogenesis and therapy of inclusion body myositis. Greenberg SA, Curr Opin Neurol 2012 25 630 639
24. Familial inflammatory inclusion body myositis. Ranque-Francois B, Maisonobe T, Dion E, Piette JC, Chauveheid MP, Amoura Z, Papo T, Ann Rheum Dis 2005 64 634 637 (Pubitemid 40469098)
25. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families. Sivakumar K, Semino-Mora C, Dalakas MC, Brain 1997 120 Pt 4 653 661 (Pubitemid 27174100)
26. Familial inclusion body myositis: a report on two Japanese sisters. Tateyama M, Saito N, Fujihara K, Shiga Y, Takeda A, Narikawa K, Hasegawa T, Taguchi Y, Sakuma R, Onodera Y, Ohnuma A, Tobita M, Itoyama Y, Intern Med 2003 42 1035 1038 (Pubitemid 37407654)
27. Inclusion body myositis in twins. Amato AA, Shebert RT, Neurology 1998 51 598 600 (Pubitemid 28406348)
28. Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. Askanas V, Engel WK, Curr Opin Neurol 2002 15 525 531 (Pubitemid 35176686)
29. Genetics of inclusion-body myositis. Needham M, Mastaglia FL, Garlepp MJ, Muscle Nerve 2007 35 549 561 (Pubitemid 46676844)
30. Partial laminin alpha2 chain deficiency in a patient with myopathy resembling inclusion body myositis. Di Blasi C, Mora M, Pareyson D, Farina L, Sghirlanzoni A, Vignier N, Blasevich F, Cornelio F, Guicheney P, Morandi L, Ann Neurol 2000 47 811 816 (Pubitemid 30390204)
31. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M, J Neuropathol Exp Neurol 2004 63 484 498 (Pubitemid 38669669)
32. Clinical, pathological, and genetic mutation analysis of sporadic inclusion body myositis in Japanese people. Cai H, Yabe I, Sato K, Kano T, Nakamura M, Hozen H, Sasaki H, J Neurol 2012 259 1913 1922
33. Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation" Dalakas MC, Ann Neurol 2008 64 1 3
34. Inflammatory, immune, and viral aspects of inclusion-body myositis. Dalakas MC, Neurology 2006 66 33 S38
35. Mitochondrial and inflammatory changes in sporadic Inclusion Body Myositis. Rygiel KA, Miller J, Grady JP, Rocha MC, Taylor RW, Turnbull DM, Neuropathol Appl Neurobiol 2014 doi:10.1111/nan.12149
36. Molecular pathology and pathogenesis of inclusion-body myositis. Askanas V, Engel WK, Microsc Res Tech 2005 67 114 120 (Pubitemid 41243629)
37. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Askanas V, Engel WK, Nogalska A, Brain Pathol 2009 19 493 506
38. Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. Jaworska-Wilczynska M, Wilczynski GM, Engel WK, Strickland DK, Weisgraber KH, Askanas V, Neurology 2002 58 438 445 (Pubitemid 34150920)
39. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. Yang CC, Alvarez RB, Engel WK, Askanas V, Neuroreport 1996 8 153 158 (Pubitemid 126785549)
40. Mutant ubiquitin UBB + 1 is accumulated in sporadic inclusion-body myositis muscle fibers. Fratta P, Engel WK, Van Leeuwen FW, Hol EM, Vattemi G, Askanas V, Neurology 2004 63 1114 1117 (Pubitemid 39287931)
41. Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Nogalska A, D'Agostino C, Terracciano C, Engel WK, Askanas V, Am J Pathol 2010 177 1377 1387
42. Sporadic inclusion body myositis: pathogenic considerations. Karpati G, O'Ferrall EK, Ann Neurol 2009 65 7 11
43. Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex. Kok CC, Croager EJ, Witt CS, Kiers L, Mastaglia FL, Abraham LJ, Garlepp MJ, Immunogenetics 1999 49 508 516 (Pubitemid 29221783)
44. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, Kong SW, Pinkus JL, Amato AA, Elledge SJ, Greenberg SA, Ann Neurol 2013 73 408 418
45. beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Askanas V, Alvarez RB, Engel WK, Ann Neurol 1993 34 551 560 (Pubitemid 23289406)
46. Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. Askanas V, Engel WK, Yang CC, Alvarez RB, Lee VM, Wisniewski T, Am J Pathol 1998 152 889 895 (Pubitemid 28173350)
47. Dysferlin is a newly identified binding partner of AbetaPP and it co-aggregates with amyloid-beta42 within sporadic inclusion-body myositis (s-IBM) muscle fibers. Cacciottolo M, Nogalska A, D'Agostino C, Engel WK, Askanas V, Acta Neuropathol 2013 126 781 783
48. Apolipoprotein epsilon alleles in sporadic inclusion body myositis: a reappraisal. Needham M, Hooper A, James I, van Bockxmeer F, Corbett A, Day T, Garlepp MJ, Mastaglia FL, Neuromuscul Disord 2008 18 150 152 (Pubitemid 351289086)
49. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M, Hum Mol Genet 1999 8 711 715 (Pubitemid 29139987)
50. Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion-body myositis. Lampe J, Kitzler H, Walter MC, Lochmuller H, Reichmann H, Lancet 1999 353 465 466 (Pubitemid 29067343)
51. Apolipoprotein E and alpha-1-antichymotrypsin polymorphisms in sporadic inclusion body myositis. Gossrau G, Gestrich B, Koch R, Wunderlich C, Schroder JM, Schroeder S, Reichmann H, Lampe JB, Eur Neurol 2004 51 215 220 (Pubitemid 38812978)
52. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PI, Kimonis V, Pestronk A, J Neurol Neurosurg Psychiatry 2008 79 1186 1189
53. Abnormal distribution of heterogeneous nuclear ribonucleoproteins in sporadic inclusion body myositis. Pinkus JL, Amato AA, Taylor JP, Greenberg SA, Neuromuscul Disord 2014 24 611 616
54. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R, Neuron 2011 72 245 256
55. Analysis of multiple mitochondrial DNA deletions in inclusion body myositis. Moslemi AR, Lindberg C, Oldfors A, Hum Mutat 1997 10 381 386 (Pubitemid 27473299)
56. Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Mastaglia FL, Rojana-Udomsart A, James I, Needham M, Day TJ, Kiers L, Corbett JA, Saunders AM, Lutz MW, Roses AD, Neuromuscul Disord 2013 23 969 974
57. HLA associations with inclusion body myositis. Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL, Clin Exp Immunol 1994 98 40 45 (Pubitemid 24315449)
58. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Badrising UA, Schreuder GM, Giphart MJ, Geleijns K, Verschuuren JJ, Wintzen AR, Maat-Schieman ML, van Doorn P, van Engelen BG, Faber CG, Hoogendijk JE, de Jager AE, Koehler PJ, de Visser M, van Duinen SG, Dutch IBM Study Group, Neurology 2004 63 2396 2398 (Pubitemid 40024360)
59. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas MC, J Neuroimmunol 1998 84 139 142 (Pubitemid 28248398)
60. Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. Lampe JB, Gossrau G, Kempe A, Fussel M, Schwurack K, Schroder R, Krause S, Kohnen R, Walter MC, Reichmann H, Lochmuller H, J Neurol 2003 250 1313 1317 (Pubitemid 37456891)
61. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Mastaglia FL, Needham M, Scott A, James I, Zilko P, Day T, Kiers L, Corbett A, Witt CS, Allcock R, Laing N, Garlepp M, Christiansen FT, Neuromuscul Disord 2009 19 763 765
62. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. Needham M, James I, Corbett A, Day T, Christiansen F, Phillips B, Mastaglia FL, J Neurol Neurosurg Psychiatry 2008 79 1056 1060
63. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Price P, Santoso L, Mastaglia F, Garlepp M, Kok CC, Allcock R, Laing N, Tissue Antigens 2004 64 575 580 (Pubitemid 39472922)
64. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. O'Hanlon TP, Carrick DM, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Dreyfuss J, Shamim EA, Rider LG, Chanock SJ, Foster CB, Bunch T, Plotz PH, Love LA, Miller FW, Medicine (Baltimore) 2005 84 338 349 (Pubitemid 41668933)
65. High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes. Rojana-udomsart A, James I, Castley A, Needham M, Scott A, Day T, Kiers L, Corbett A, Sue C, Witt C, Martinez P, Christiansen F, Mastaglia F, J Neuroimmunol 2012 250 77 82
66. Sporadic inclusion body myositis in Japanese is associated with the MHC ancestral haplotype 52.1. Scott AP, Allcock RJ, Mastaglia F, Nishino I, Nonaka I, Laing N, Neuromuscul Disord 2006 16 311 315
67. Analysis of HLA-DRB3 alleles and supertypical genotypes in the MHC Class II region in sporadic inclusion body myositis. Rojana-udomsart A, Mitrpant C, James I, Witt C, Needham M, Day T, Kiers L, Corbett A, Martinez P, Wilton SD, Mastaglia FL, J Neuroimmunol 2013 254 174 177
68. Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex. Scott AP, Laing NG, Mastaglia F, Needham M, Walter MC, Dalakas MC, Allcock RJ, J Neuroimmunol 2011 235 77 83
69. Investigation of NOTCH4 coding region polymorphisms in sporadic inclusion body myositis. Scott AP, Laing NG, Mastaglia F, Dalakas M, Needham M, Allcock RJ, J Neuroimmunol 2012 250 66 70
70. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. Salajegheh M, Lam T, Greenberg SA, PLoS One 2011 6 20266
71. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, Verbeek MM, Badrising UA, Arnardottir S, Gheorghe K, Lundberg IE, Boelens WC, van Engelen BG, Pruijn GJ, Ann Neurol 2013 73 397 407
72. The functional logic of cytosolic 5′-nucleotidases. Ipata PL, Balestri F, Curr Med Chem 2013 20 4205 4216
73. Beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis. Askanas V, Engel WK, Alvarez RB, Glenner GG, Lancet 1992 339 560 561
74. Beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB, Neuroreport 1993 4 815 818 (Pubitemid 23190926)
75. Identification of physiological and toxic conformations in Abeta42 aggregates. Masuda Y, Uemura S, Ohashi R, Nakanishi A, Takegoshi K, Shimizu T, Shirasawa T, Irie K, Chembiochem 2009 10 287 295
76. Novel demonstration of amyloid-beta oligomers in sporadic inclusion-body myositis muscle fibers. Nogalska A, D'Agostino C, Engel WK, Klein WL, Askanas V, Acta Neuropathol 2010 120 661 666
77. Increased plasma amyloid-beta42 protein in sporadic inclusion body myositis. Abdo WF, van Mierlo T, Hengstman GJ, Schelhaas HJ, van Engelen BG, Verbeek MM, Acta Neuropathol 2009 118 429 431
78. Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. Sivakumar K, Cervenakova L, Dalakas MC, Leon-Monzon M, Isaacson SH, Nagle JW, Vasconcelos O, Goldfarb LG, Ann Neurol 1995 38 267 269
79. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Weggen S, Beher D, Alzheimers Res Ther 2012 4 9
80. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Vetrivel KS, Thinakaran G, Neurology 2006 66 69 S73
81. Translational research and therapeutic perspectives in dysferlinopathies. Barthelemy F, Wein N, Krahn M, Levy N, Bartoli M, Mol Med 2011 17 875 882
82. Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. Mirabella M, Alvarez RB, Engel WK, Weisgraber KH, Askanas V, Ann Neurol 1996 40 864 872 (Pubitemid 27044604)
83. Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases. Askanas V, Mirabella M, Engel WK, Alvarez RB, Weisgraber KH, Lancet 1994 343 364 365 (Pubitemid 24043208)
84. Apolipoprotein E epsilon 4 in inclusion body myositis. Garlepp MJ, Tabarias H, van Bockxmeer FM, Zilko PJ, Laing B, Mastaglia FL, Ann Neurol 1995 38 957 959 (Pubitemid 26004079)
85. Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Askanas V, Engel WK, Mirabella M, Weisgraber KH, Saunders AM, Roses AD, McFerrin J, Ann Neurol 1996 40 264 265 (Pubitemid 26274566)
86. Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis. Harrington CR, Anderson JR, Chan KK, Neurosci Lett 1995 183 35 38
87. Apolipoprotein E allele frequencies in sporadic inclusion body myositis. Love S, Nicoll JA, Lowe J, Sherriff F, Muscle Nerve 1996 19 1605 1607 (Pubitemid 26412118)
88. Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Maurage CA, Bussiere T, Sergeant N, Ghesteem A, Figarella-Branger D, Ruchoux MM, Pellissier JF, Delacourte A, Neuropathol Appl Neurobiol 2004 30 624 634 (Pubitemid 39564182)
89. The molecular genetics of the tauopathies. van Slegtenhorst M, Lewis J, Hutton M, Exp Gerontol 2000 35 461 471 (Pubitemid 30665822)
90. Strong immunoreactivity of alpha 1-antichymotrypsin co-localizes with beta-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusion-body myositis. Bilak M, Askanas V, Engel WK, Acta Neuropathol 1993 85 378 382 (Pubitemid 23100926)
91. APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST, Nat Genet 1995 10 486 488
92. Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Sarkozi E, Askanas V, Engel WK, Am J Pathol 1994 145 1280 1284 (Pubitemid 24378481)
93. Prion protein is abnormally accumulated in inclusion-body myositis. Askanas V, Bilak M, Engel WK, Alvarez RB, Tome F, Leclerc A, Neuroreport 1993 5 25 28 (Pubitemid 23330812)
94. Prion codon 129 homozygosity and sporadic inclusion body myositis. Lampe J, Gossrau G, Reichmann H, Walter MC, Mendel B, Lochmuller H, Neurology 2001 57 368 (Pubitemid 32667388)
95. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF, Camu W, Meininger V, Dupre N, Rouleau GA, Nat Genet 2008 40 572 574 (Pubitemid 351601218)
96. Abnormal TDP-43 and FUS proteins in muscles of sporadic IBM: similarities in a TARDBP-linked ALS patient. Hernandez Lain A, Millecamps S, Dubourg O, Salachas F, Bruneteau G, Lacomblez L, LeGuern E, Seilhean D, Duyckaerts C, Meininger V, Mallet J, Pradat PF, J Neurol Neurosurg Psychiatry 2011 82 1414 1416
97. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. Olive M, Janue A, Moreno D, Gamez J, Torrejon-Escribano B, Ferrer I, J Neuropathol Exp Neurol 2009 68 262 273
98. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Salajegheh M, Pinkus JL, Taylor JP, Amato AA, Nazareno R, Baloh RH, Greenberg SA, Muscle Nerve 2009 40 19 31
99. Altered ribostasis: RNA-protein granules in degenerative disorders. Ramaswami M, Taylor JP, Parker R, Cell 2013 154 727 736
100. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, Kanagaraj AP, Carter R, Boylan KB, Wojtas AM, Rademakers R, Pinkus JL, Greenberg SA, Trojanowski JQ, Traynor BJ, Smith BN, Topp S, Gkazi AS, Miller J, Shaw CE, Kottlors M, Kirschner J, Pestronk A, Li YR, Ford AF, Gitler AD, et al. Nature 2013 495 467 473
101. Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Bieniek KF, Murray ME, Rutherford NJ, Castanedes-Casey M, DeJesus-Hernandez M, Liesinger AM, Baker MC, Boylan KB, Rademakers R, Dickson DW, Acta Neuropathol 2013 125 289 302
102. Ragged red fibers in normal aging and inflammatory myopathy. Rifai Z, Welle S, Kamp C, Thornton CA, Ann Neurol 1995 37 24 29
103. Mitochondrial DNA deletions in inclusion body myositis. Oldfors A, Larsson NG, Lindberg C, Holme E, Brain 1993 116 Pt 2 325 336 (Pubitemid 23104050)
104. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Santorelli FM, Sciacco M, Tanji K, Shanske S, Vu TH, Golzi V, Griggs RC, Mendell JR, Hays AP, Bertorini TE, Pestronk A, Bonilla E, DiMauro S, Ann Neurol 1996 39 789 795 (Pubitemid 26183815)
105. Mitochondrial DNA variants in inclusion body myositis. Kok CC, Boyt A, Gaudieri S, Martins R, Askanas V, Dalakas M, Kiers L, Mastaglia F, Garlepp M, Neuromuscul Disord 2000 10 604 611
106. TOMM40 association with Alzheimer disease: tales of APOE and linkage disequilibrium. Guerreiro RJ, Hardy J, Arch Neurol 2012 69 1243 1244
107. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M, Proc Natl Acad Sci U S A 2008 105 13145 13150
108. TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. Roses AD, Lutz MW, Crenshaw DG, Grossman I, Saunders AM, Gottschalk WK, Alzheimers Dement 2013 9 132 136
109. TREM2 variants in Alzheimer's disease. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis Group, N Engl J Med 2013 368 117 127
110. Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. Guerreiro R, Bras J, Hardy J, Singleton A, Hum Mol Genet 2014 doi:10.1093/hmg/ddu203